Silexion Therapeutics (SLXN) announced the completion of a comprehensive preclinical study assessing SIL204’s therapeutic potential across multiple cancer types beyond pancreatic cancer. The Company is currently finalizing its analysis of the data and expects to announce comprehensive results within the next few days. The now-completed studies evaluated SIL204, the Company’s next-generation RNAi therapeutic candidate, in multiple cancer cell lines harboring KRAS mutations: GP2D, A427, and Panc-1. These cancer types were strategically selected based on their high prevalence of KRAS mutations and significant unmet medical needs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLXN:
- Silexion Therapeutics’ Promising Future: Buy Rating Backed by Expanding Market Potential and Strong Financial Position
- Silexion Therapeutics Partners with Catalent for SIL204 Development
- Silexion Therapeutics enters collaboration with Catalent
- Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion
- Silexion Therapeutics Expands SIL204 Development Plan